Improved drug transfer into brain tissue via the “nose-to-brain” approach using suspension or powder formulations based on the amorphous solid dispersion technique
European Journal of Pharmaceutics and Biopharmaceutics · 2023-04 · 185 · 137-147
DOI: 10.1016/j.ejpb.2023.02.012 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Pharmaceutics and Biopharmaceutics, 2023-04. Verfasst von Susumu Suwabe und 3 weiteren Autor:innen. Beteiligte Einrichtung: Drug Delivery and Nano Pharmaceutics, Graduate School of Pharmaceutical Sciences, Nagoya City University, 3-1 Tanabe-dori, Mizuho-ku, Nagoya, Aichi 4…. Hauptthemen laut MEDLINE: Chemistry, Pharmaceutical, Water. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 33 Literaturangaben. Gefördert von: Japan Science and Technology Agency.
Abstract (Originalsprache)
Intranasal administration has attracted increasing attention as a drug delivery approach based on nose-to-brain drug delivery from the nasal cavity to brain tissue directly, bypassing the blood-brain barrier. However, application of the method to poorly water-soluble drugs is potentially limited due to low aqueous solubility and dissolution, which can hinder drug transfer to brain tissue. In the present study, we focused on an amorphous solid dispersion (ASD) technique to improve drug dissolution. A carbamazepine-loaded ASD model drug was prepared using the solvent evaporation method (ASD-1). After screening six water-soluble polymer carriers, polyvinyl alcohol (PVA)-based ASD-1 formulation exhibited the most rapid and highest drug dissolution under experimental conditions in the nasal cavity (pH 6.0). A carbamazepine suspension dispersed with a PVA-ASD-1 formulation exhibited enhanced drug delivery into plasma and brain tissue of rats in vivo. A spray-dried powder formulation of PVA-ASD (PVA-ASD-2) exhibited improved drug dissolution and in vivo drug transfer. Our key finding is that the spray-dried PVA-ASD-2 formulation exhibited higher brain/plasma ratios than the PVA-ASD-1 suspension formulation. Our physical characterization data and demonstration of improved drug transfer suggest that ASD-based intranasal formulations hold promise for drug delivery to the brain.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Drug Delivery and Nano Pharmaceutics, Graduate School of Pharmaceutical Sciences, Nagoya City University, 3-1 Tanabe-dori, Mizuho-ku, Nagoya, Aichi 467-8603, Japan.
- Drug Delivery and Nano Pharmaceutics, Graduate School of Pharmaceutical Sciences, Nagoya City University, 3-1 Tanabe-dori, Mizuho-ku, Nagoya, Aichi 467-8603, Japan. Electronic address: ozekit@phar.nagoya-cu.ac.jp.
Förderung
- Japan Science and Technology Agency
Zitieren
APA
Suwabe, S., Tagami, T., Ogawa, K., & Ozeki, T. (2023). Improved drug transfer into brain tissue via the “nose-to-brain” approach using suspension or powder formulations based on the amorphous solid dispersion technique. European Journal of Pharmaceutics and Biopharmaceutics, 185, 137-147. https://doi.org/10.1016/j.ejpb.2023.02.012
Vancouver
Suwabe S, Tagami T, Ogawa K, Ozeki T. Improved drug transfer into brain tissue via the “nose-to-brain” approach using suspension or powder formulations based on the amorphous solid dispersion technique. European Journal of Pharmaceutics and Biopharmaceutics. 2023;185:137-147. doi:10.1016/j.ejpb.2023.02.012
BibTeX
@article{Suwabe2023,
author = {Suwabe, Susumu and Tagami, Tatsuaki and Ogawa, Koki and Ozeki, Tetsuya},
title = {Improved drug transfer into brain tissue via the “nose-to-brain” approach using suspension or powder formulations based on the amorphous solid dispersion technique},
journal = {European Journal of Pharmaceutics and Biopharmaceutics},
year = {2023},
volume = {185},
pages = {137--147},
doi = {10.1016/j.ejpb.2023.02.012}
}
EUVIMED